Efficacy and Safety of Microtransplantation for Advanced and Relapsed Solid Tumors

Starting soon · Phase 1

Conditions studied: Advanced and Relapsed Solid Tumors

In brief

In this study, microtransplantation (MST) will be administrated to patients diagnosed with advanced / relapsed solid tumors to assess the therapeutic efficacy and safety of conventional chemotherapy in combination with MST for the treatment of advanced/relapsed solid tumors.

Key facts

Study ID

NCT07356856

Run by

The Affiliated Hospital of the Chinese Academy of Military Medical Sciences

People needed

10

Starts

2026-01-15

Expected to finish

2028-06-01

Last updated by the study team

2026-01-21

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients are 18 to 90 years old, regardless of gender or race;
• Advanced / relapsed solid tumors (small cell lung cancer, ovarian cancer, cervical cancer, gastric and colorectal cancer, sarcoma, head and neck tumor, etc.) are confirmed by clinical or histopathological diagnosis;
• More than two kinds of tumors are allowed;
• Karnofsky score ≥ 40, ECoG physical status ≤ 3;
• There are measurable lesions;

You may not qualify if…

• The researchers considered patients who were not suitable to participate in this experiment；
• Patients with mental disorders；
• Patients who refuse to cooperate with the treatment；

Where it is running

• Innovvy(Beijing) Biomedical Technology Co., Ltd — Haidian, Beijing Municipality, China
• Minzu Hospital of Guangxi Zhuang Autonomous Region — Nanning, Guangxi, China
• The First People's Hospital of Nanning — Nanning, Guangxi, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.